drugset / Trial / NCT02637999

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

NCT02637999

Phase 1/2 Completed 24 enrolled Hepatera Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).

Timeline

Start
2014-02-13
Primary completion
2016-01-21
Completion
2016-01-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Myrcludex B Peptide 2 mg
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug